Project description
European infrastructure for the development of human and veterinary vaccines
The EU-funded TRANSVAC-DS project aims to further explore and advance the establishment of a Pan-European vaccine infrastructure, based on the achievements of the previous TRANSVAC1/2 projects which since the beginning in 2009 are providing significant support to the development of human and veterinary prophylactic and therapeutic vaccines. The TRANSVAC-DS consortium consists of 25 partners from ten EU Member States and Associated Countries and includes leading organisations from the European vaccine research and development field. The main output of TRANSVAC-DS will be a conceptual design report, including a five-year business plan together with an implementation plan, that will describe in detail the maturity of the concept and be the basis for the establishment of a permanent and sustainable vaccine infrastructure.
Objective
The TRANSVAC-DS project further builds on the outstanding success of EC-funded projects:TRANSVAC1 and TRANSVAC2 and proposes the establishment of a truly sustainable European vaccine infrastructure, which will build upon the lessons learned, activities and achievements of the TRANSVAC1/2 projects.
Two infrastructure projects -TRANSVAC1 and TRANSVAC2- have been funded by the European Commission which -through the provision of state-of-the-art scientific-technical vaccine development services, technical training, and innovative vaccine research and development- have provided very significant support to European vaccine researchers and developers. Support has been, and is being provided to the development of human and veterinary prophylactic and therapeutic vaccines.
The twenty-five partners in the TRANSVAC-DS consortium that will contribute to the outcome of the project represent ten EU Member States and Associated Countries and include leading organisations from the European vaccine R&D field.
The main output of TRANSVAC-DS will be a conceptual design report that will describe in detail the maturity of the concept and be the basis for the establishment of a permanent and sustainable vaccine infrastructure of direct relevance to and benefit for Europe and further afield. As part of the design report, a five-year business plan will be delivered together with an implementation plan that will guide the further establishment of a sustainable European vaccine infrastructure.
Fields of science
Keywords
Programme(s)
Funding Scheme
RIA - Research and Innovation actionCoordinator
69115 Heidelberg
Germany
See on map
Participants (27)
69007 Lyon
See on map
2288 GJ Rijswijk Zh
See on map
75014 Paris
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
1099 085 Lisboa
See on map
1081 HZ Amsterdam
See on map
3590 Diepenbeek
See on map
80686 Munchen
See on map
2781 901 Oeiras
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
38124 Braunschweig
See on map
75015 PARIS 15
See on map
08140 Caldes De Montbui Barcelona
See on map
75007 Paris
See on map
Participation ended
2500 EJ Den Haag
See on map
2781-901 Oeiras
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
28029 Madrid
See on map
OX4 2JY Oxford
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
50121 FIRENZE
See on map
2333 ZA Leiden
See on map
WC1E 7HT London
See on map
E14 4PU London
See on map
53100 Siena
See on map
1050 Elsene
See on map
2300 Kobenhavn S
See on map
53100 Siena
See on map
1228 Plan Les Ouates
See on map
6708 PB Wageningen
See on map
3721 MA Bilthoven
See on map